Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

As Expected: Shareholders Back Bristol's $74bn Celgene Buy

Apr 12 2019

• By Mandy Jackson

Yes-No — Bristol and Celgene shareholders endorsed their merger April 12. • Source: Shutterstock

Related Content

Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond

Jan 09 2018

Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety

Sep 12 2018

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Jan 04 2019

Bristol/Celgene A Record-Setting Merger, If It Happens

Jan 04 2019

Bristol Approached Celgene Nearly Two Years Ago, Got A Better Deal Later

Feb 01 2019

Will Shareholders Support The Bristol/Celgene Merger? – An Informa Pharma Intelligence Podcast

Mar 29 2019

Celgene/Bristol's Revlimid Patent Risk Incrementally Lower After PTAB Denies Alvogen IPR

Mar 15 2019

Poseida, Legend/Janssen Look To Snag Celgene/Bluebird's BCMA Crown

Dec 04 2018

CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market

Jan 04 2019

'Totality Of Data' Make A Case For Luspatercept In Beta-Thalassemia, MDS

Dec 03 2018

More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS

Feb 28 2018

Related Companies

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Acceleron Pharma, Inc.

Pfizer Inc.

Pfizer Inc.

GSK plc

GSK plc

Additional Topics

Deals Business Strategies Strategy Companies Commercial BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window